Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

71.45 EUR

+0.42 %

14,397 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

+0.42 %
-4.92 %
+3.18 %
+12.25 %
+19.48 %
+24.48 %
+73.84 %
+94.53 %
+536.24 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
10.08B EUR
Turnover
15.42M EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
24.04.2026
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7.
2026

Interim report Q2'26

19.10.
2026

Half year dividend

28.10.
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Views on Orion’s share price can validly be presented within a fairly wide range. This €60 is fine, Inderes’s (Inden) €80 is fine, and the €100 presented by Erkki Sinkko in the media is also fine. This isn’t a bargain-bin stock, but cash is flowing in massively, all the company’s...
4/24/2026, 6:58 AM
by PörssiPatruuna
20
Orion’s results are out, guidance raised as well: Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026 | Kauppalehti January–March 2026 in brief Net sales were EUR 417.7 million (EUR 354.6 million in 1–3/2025) Operating profit was EUR 114.8 (77.9) million Basic earnings per share...
4/23/2026, 9:12 AM
by NukkeNukuttaja
14
R&D expenses as a percentage of revenue were 11.6% in Q1’26. In the comparison period, Q1’25, the ratio was… 11.6%.
4/23/2026, 10:59 AM
by Verneri Pulkkinen
12
An article in Kauppalehti suggests that Orion’s stock drop today is due to a sharp increase in research and development expenses. On the contrary, a long-term investor should be pleased with significant R&D boosts, especially in the pharmaceutical industry. Overall, it’s a solid,...
4/23/2026, 9:32 AM
by PörssiPatruuna
10
Here’s a new company report from Siltanen after Q1. Orion’s Q1 was again strong and in line with our expectations. Revenue grew by 18% and operating profit by 47%, supported by Nubeqa’s high-margin growth. Among other business areas, Branded Products developed particularly well with...
4/24/2026, 6:11 AM
by Sijoittaja-alokas
9
Here is Liisa’s interview regarding Orion’s development. Inderes Orion Q1’26: Strategian mukaista kasvua - Inderes Aika: 23.04.2026 klo 15.30 Orionin voimakas kasvu jatkuu strategian mukaisesti Nubeqa kärjessä. Toimitusjohtaja Liisa Hurme kommentoi. 00:00 Orion’s development 00:50...
4/23/2026, 1:30 PM
by Verneri Pulkkinen
8
Orion Animal Health receives FDA approval for Tessie® (tasipimidine oral solution) ORION CORPORATION PRESS RELEASE MAY 12, 2026, AT 10:30 AM Orion Animal Health receives FDA approval for Tessie® (tasipimidine oral solution) Orion Corporation received approval from the U.S. Food and...
5/12/2026, 7:47 AM
by Dissidentti
7
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.